endothelial cells (ecs) have essential roles in organ development and regeneration, and therefore they could be used for regenerative therapies. However, generation of abundant functional endothelium from pluripotent stem cells has been difficult because ecs generated by many existing strategies have limited proliferative potential and display vascular instability. the latter difficulty is of particular importance because cells that lose their identity over time could be unsuitable for therapeutic use. Here, we describe a 3-week platform for directly converting human mid-gestation lineage-committed amniotic fluid-derived cells (acs) into a stable and expandable population of vascular ecs (rac-Vecs) without using pluripotency factors. By transient expression of the ets transcription factor ETV2 for 2 weeks and constitutive expression the ets transcription factors FLI1 and ERG1, concomitant with tGF-b inhibition for 3 weeks, epithelial and mesenchymal acs are converted, with high efficiency, into functional rac-Vecs. these rac-Vecs maintain their vascular repertoire and morphology over numerous passages in vitro, and they form functional vessels when implanted in vivo. rac-Vecs can be detected in recipient mice months after implantation. thus, rac-Vecs can be used to establish a cellular platform to uncover the molecular determinants of vascular development and heterogeneity and potentially represent ideal ecs for the treatment of regenerative disorders.
IntroDuctIon
The ability to generate large numbers of human ECs would significantly augment therapies that target a variety of vasculardependent maladies, including vessel damage, organ failure and hematopoietic dysfunction. A multitude of studies have shown that ECs contribute to tissue regeneration after liver and lung damage [1] [2] [3] , facilitate bone marrow recovery [4] [5] [6] [7] [8] , and can directly engraft into host vasculature 9 . Recent work has also shown that ECs are essential as instructive niches for the generation of hematopoietic cells and functional hepatocytes by reprogramming 10, 11 . Thus, the development of a protocol that generates large amounts of pure and stable ECs would advance the development of novel treatments for vascular-related disorders, as well as treatments of diseases of different organ systems.
Cultivation of sufficient stable ECs for clinical applications has thus far proven to be exceedingly difficult. Mature or adultderived ECs, such as human umbilical vein ECs (HUVECs) or liver sinusoidal ECs (LSECs), can only be passaged for a limited time in vitro. Therefore, many groups have generated ECs by directed differentiation of pluripotent cells or lineage conversion of other somatic cells [12] [13] [14] [15] [16] [17] [18] [19] [20] . The protocol described here, first used by Ginsberg et al. 21 , uses a direct conversion strategy and has unequaled efficiency; after 3 weeks, converted cells expand nearly 100-fold, and they are >80% VE-cadherin-positive 21 .
Comparison between directed differentiation and lineage conversion strategies Directed differentiation, compared with lineage conversion, more closely recapitulates the lineage specification that occurs during development, and it does not require overexpression of reprogramming factors. Directed differentiation of embryonic stem cells (ESCs) to ECs is typically 10-50% efficient 13, [17] [18] [19] [20] .
In addition, ESC-ECs that are generated in this manner are not stably or fully committed 13, 19 , nor can they be broadly human leukocyte antigen (HLA)-matched. ECs generated from directed differentiation of induced pluripotent stem cells (IPSCs) can be autologously transplanted, and two studies reported very high efficiencies, generating millions 16 and trillions of ECs 14 . However, induced pluripotency-based techniques have led to tumorigenicity and immunogenicity, which are important potential disadvantages of such methods [22] [23] [24] . ECs derived from IPSCs also display varying degrees of stability and commitment. Although one group reported stable and homogeneous cells for over 18 passages 14 , another protocol generated bipotent progenitors that gave rise to smooth muscle and endothelial lineages 16 . Thus, lineage conversion of somatic cells to ECs may be safer because the starting population is more stable, and contaminating, unconverted cells are less likely to endanger recipients.
Although conversion of adult fibroblasts to ECs is appealing because cells can be autologously transplanted, the processes used thus far are only ~10% efficient 15 . Meanwhile, conversion of amniotic cells is far more efficient (80-90%), although it should be noted that products from both cell types do not express all endothelial genes 15, 21 . Indeed, a recent wide-ranging study showed that somatic cell conversion using fibroblasts is typically incomplete because the original lineage signature is difficult to erase 25 . Nevertheless, if the goal is to generate cells for therapeutic use in long-term engraftment, stability is paramount.
The varying efficiencies and stabilities associated with ECs generated in these studies, which are seen even when the same starting populations are used, highlight a need for consistency among the groups pursuing these ends and detailed protocols, such as this.
Direct conversion of human amniotic cells into endothelial cells without transitioning through a pluripotent state
Rationale for this protocol The protocol described here uses ACs as the starting population. ACs are obtained via amniocentesis during the mid-gestation period of human fetal development. Although this is an invasive procedure, 200,000 amniocentesis procedures are performed every year for diagnostic purposes, and after clinical analyses the cells are usually discarded. This results in a large number of ACs from diverse genetic backgrounds being obtained by cytogenetics facilities. This could enable the development of a HLA-matched library of source cells, which is currently not available from human ESC collections 26 . Several groups have had limited success in differentiating ACs into EC-like cells using defined growth conditions, and others have shown that these cells display lineage plasticity [27] [28] [29] [30] . This plasticity may underlie their amenability to endothelial reprogramming, which is similar to the superior efficiency of embryonic fibroblasts, compared with adult cells, in several reprogramming strategies [31] [32] [33] [34] . It is unknown whether the increased efficiency of amniotic cells is common to all mid-gestation tissue or whether it is unique to amniotic cells. This issue should be addressed by comparing the convertibility of different amniotic tissues, such as a term amniotic mesenchymal stromal cells, which are present in the placenta 35 .
In a recent study, we demonstrated that ACs constitute a novel source of abundant and readily accessible nonvascular cells that can be reprogrammed into vascular ECs (rAC-VECs) with defined transcription factors (TFs). rAC-VECs possess an angiogenic and vascular functional profile that matches mature bona fide ECs 21 . The reprogramming platform that we used, and describe here, does not require the addition of pluripotency factors, and this augments the durability and stability of these highly proliferative rAC-VECs. As numerous studies had documented the role of the E-twenty six (ETS) family of TFs (ETS-TFs) as essential regulators of vascular development and angiogenesis [36] [37] [38] [39] [40] [41] [42] [43] , we surmised that these TFs could be ideal candidates for reprogramming nonvascular cells into ECs. After a lengthy screening process using numerous ETS-TFs (as well as several non-ETSfamily TFs), we identified ETV2, ERG1 and FLI1 to be the most efficient factors for reprogramming ACs into rAC-VECs 21 . Through overexpression of these ETS-TFs along with short-term inhibition of transforming growth factor (TGF)-β signaling, we successfully generated a population of expandable ECs that were stable over numerous passages in vitro, and engrafted into mouse host microvasculature where they remained viable for 3 months. To recapitulate developmental programs, overexpression of ETV2 for only 2 weeks was sufficient to complete the reprogramming process into rAC-VECs. Global transcriptome analyses demonstrated that rAC-VECs express a vascular signature that is nearly identical to that of other mature EC populations, such as HUVECs and LSECs, while differing significantly from nonvascular cell types. This comprehensive genome-wide analysis also revealed that the ES-derived EC expression profile was markedly different from that of the rAC-VEC, HUVEC and LSEC profiles, accentuating the notion that ACs may represent a preferable cell source to pluripotent stem cells for reprogramming.
Experimental design
The principle components of this protocol include the transduction of ACs with specific ETS-TFs (via lentiviral infection) and the use of culture conditions that suppress TGFβ signaling. The time frame of this platform is ~3 weeks, beginning with the initial lentiviral infection of ACs with ETV2, ERG1 and FLI1. Examination of gene expression (via qPCR analysis 21 ) and surface marker presentation (via FACS analysis 21 ) revealed that ACs transduced with these ETS-TFs gradually acquire an EC phenotype during the reprogramming process (Fig. 1a) , whereas untransduced ACs do not. By the fourth week of the protocol (days 21-28), rAC-VECs are established. They demonstrate a robust proliferative potential and are stable, having acquired a global transcriptome profile that is highly similar to other authentic EC populations, including HUVECs and LSECs 21 . We have confirmed that the rAC-VECs obtained using the protocol were not derived from pre-existing endothelial precursor or pluripotent subpopulations of amniotic cells, as rAC-VECs could have been generated from such populations by simply incubating them with endothelial growth conditions (Fig. 1b) REAGENT SETUP AC growth medium AC growth medium contains AmnioMax base medium, AmnioMax supplement and 100 U ml −1 antibiotic-antimycotic. To prepare 500 ml of AC medium, add the entire bottle of AmnioMax supplement into AmnioMax base medium, and mix it in 5 ml of antibiotic-antimycotic solution.
 crItIcal Filter-sterilize the medium in a 500-ml filter system 0.22-µm bottle; store the medium in the dark at 4 °C and use it within 4 weeks.
Alternative platform described in the protocol. Although ETV2, ERG1 and FLI1 are highly effective in the generation of rAC-VECs from ACs, our initial studies revealed that several key EC genes remained inactive in these reprogrammed cells, including CD31 (officially known as PECAM1). Because it had been previously reported that ETV2 is only expressed briefly during embryonic development and that it is seemingly absent in nearly all adult EC beds 39 , we designed a conditionally active ETV2 (TRE-ETV2) construct that could be suppressed with doxycycline in vitro, thus partially mimicking the physiological expression pattern of ETV2 in vivo. In this modified platform, ACs are transduced with TRE-ETV2 (in addition to constitutively active ERG1 and FLI1) for 2 weeks, at which time doxycycline is introduced into the growth medium. By week 4 of the protocol (i.e., 7-14 d after ETV2 is turned off), rAC-VECs are established. However, CD31 proteins and numerous other mature vascular specific genes are expressed in these cells, suggesting that abbreviated induction of ETV2 is ideal for the generation of mature rAC-VECs. Incidentally, ACs transduced with only ERG1 and FLI1 (i.e., in the absence of ETV2) fail to generate rAC-VECs, as these cells do not proliferate efficiently beyond 4 weeks post lentiviral transduction, suggesting that initial induction with ETV2 is essential for specification of amniotic cells into rAC-VECs. Last, it should be noted that although rAC-VECs generated with TRE-ETV2 are still highly proliferative, these cells will expand to a lesser degree than rAC-VECs produced with constitutively active ETV2. Thus, we also describe the generation of rAC-VECs with conditional TRE-ETV2 below. 
Box 1 | Lentiviral production • tIMInG ~1 week
We generate lentiviruses using the Xfect transfection reagent, the Lenti-X HTX packaging system and the Lenti-X concentrator (along with their corresponding protocols), all from Clontech. We titer lentiviruses using the Lenti-X p24 rapid titer kit, also from Clontech. A brief outline of the lentiviral preparation and some important points to bear in mind are given below. antibiotic-antimycotic. To prepare 500 ml of lentiviral growth medium, add 55 ml of FBS to a 500-ml bottle of DMEM/high-glucose medium and mix in 5.5 ml of antibiotic-antimycotic solution.  crItIcal Filter-sterilize the medium in a 500-ml filter system 0.22-µm bottle and store the medium in the dark at 4 °C; use it within 4 weeks.
Materials
• Lentiviral storage buffer. Lentiviral storage buffer contains 50 mM Tris (pH 7.8), 1 mM EDTA and 130 mM NaCl all dissolved in water.
To prepare 50 ml of lentiviral storage buffer, mix 2.5 ml of 1 M Tris with 0.1 ml of 500 mM EDTA and 1.3 ml of 5 M NaCl. Bring it up to 50 ml with water and filter-sterilize it through a 0.2-µm syringe filter. Store it at 4 °C (good for at least 1 year).
procedure ! cautIon This procedure should be conducted in a tissue culture hood, and waste products should be disposed of properly.  crItIcal step The number of 293-plated dishes to make virus is at the discretion of the researcher. At least one 10-cm dish per construct (i.e., ETV2, ERG1 and FLI1) is required for producing the viruses necessary to generate rAC-VECs. In addition, lentivirus for the pTA (trans-activator plasmid, for the TRE-expression system) construct must be made here as well, if the researcher wishes to use TRE-ETV2 construct in place of the constitutive ETV2 construct in the reprogramming platform. Generally, one 10-cm dish per construct will generate sufficient virus for several experiments. However, it is recommended that large quantities of virus be produced during a single virus preparation whenever possible, such that batch-to-batch variations are kept to a minimum. As such, we usually plate three or four 10-cm dishes of HEK 293T cells per construct (i.e., three or four dishes each for ETV2, ERG1, FLI1, TRE-ETV2 and pTA), which will afford a large stockpile of virus that can be used over many months. To do this, simply expand the HEK 293T cells in lentiviral growth medium (steps 2 and 3 in this box) until the desired number of cells has been attained for lentiviral preparation. 5. After 18-24 h, the cells should be ~60-70% confluent. Prepare the Polyfect/DNA complexes as directed by the manufacturer's instructions (Clontech, cat. no. 631318 and cat. no. 631249). Add Polyfect/DNA complexes dropwise onto the cells and place the dish in a 37 °C incubator. 6. After 12-18 h, aspirate the medium and refeed it with 8 ml of lentiviral growth medium. When you are adding fresh medium to the cells, do so very slowly and gently, as the cells can detach from the dish quite easily at this stage. Place the dish in a 37 °C incubator. 7. After 36-48 h, collect the supernatant (medium) from each dish and transfer it to 50-ml conical tubes. Supernatant from multiple dishes of the same viral preparation (i.e., multiple dishes that are all producing the ERG1 virus) can be combined and added to the same 50-ml conical tube. 
SB431542 preparation
To prepare aliquots of SB431542 for endothelial growth medium, add 470 µl of DMSO to 10 mg of SB431542. This will generate a 50 mM stock (10,000×) solution of SB431542. Dispense 50-µl aliquots of stock solution into tubes and store them at −80 °C (stable for at least 1 year). When you are preparing 500 ml of endothelial growth medium, thaw out and mix it in one aliquot (50 µl) of SB431542. Endothelial growth medium Endothelial growth medium contains medium 199, supplemented with 15% (vol/vol) FBS, 15 mM HEPES, 50 µg ml −1 EC supplement, 50 µg ml −1 heparin, 100 U ml −1 antibiotic-antimycotic, 2 mM l-glutamine and 5 µM SB431542. To prepare 500 ml of endothelial growth medium, mix together 75 ml of FBS, 7.5 ml of HEPES, 5 ml of antibioticantimycotic solution, 5 ml of l-glutamine, 25 mg of heparin, 25 mg of EC supplement and one aliquot (50 µl) of SB431542, and fill it to 500 ml with medium 199.  crItIcal Filter-sterilize the medium in a 500-ml filter system 0.22-µm bottle and store the medium in the dark at 4 °C; use it within 4 weeks.  crItIcal We have shown that using the TGF-β ligandneutralizing monoclonal antibody in place of SB431542 is equally effective in blocking TGF-β signaling in this platform. If desired, add 10 µg ml −1 TGF-β ligand-neutralizing monoclonal antibody every 2-3 d to cells cultured in endothelial growth medium prepared without SB431542. Defined serum-free medium Defined serum-free medium is a knockout serum replacement (KSR)-based medium supplemented with VEGF-A and FGF-2 that can be used as an alternative to endothelial growth medium. Defined serum-free medium contains advanced DMEM/F12, supplemented with 20% (vol/vol) KSR, 50 µg ml −1 heparin, 100 U ml −1 antibiotic-antimycotic, 2 mM l-glutamine, 10 ng ml −1 FGF, 20 ng ml −1 VEGF-A and 5 µM SB431542. To prepare 500 ml of defined serum-free medium, mix together 100 ml of KSR, 5 ml of antibiotic-antimycotic solution, 5 ml of l-glutamine, 25 mg of heparin, 5 µg of FGF-2, 10 µg of VEGF-A and one aliquot (50 µl) of SB431542, and fill it to 500 ml with advanced DMEM/F12.  crItIcal Filter-sterilize the medium in a 500-ml filter system 0.22-µm bottle and store the medium in the dark at 4 °C; use it within 4 weeks.
Box 1 | (Continued)
8. Centrifuge the supernatant at 400g for 5 min at 4 °C (this will pellet any cellular debris). Using care not to disrupt the pellet, filter the supernatant through a 0.45-µm syringe filter into new 50-ml conical tubes (for large volumes of supernatant, 150 ml filter system 0.45-µm bottles can be used).  crItIcal step When you are filtering the supernatant, only use cellulose acetate or polyethersulfone (PES) low-protein-binding filters. 9. For every three volumes of filtered supernatant, add one volume of Lenti-X concentrator (i.e., for 15 ml of supernatant, add 5 ml of Lenti-X concentrator). Mix it by inversion, and place it at 4 °C for at least 1 h.  pause poInt After the addition of Lenti-X concentrator, samples can be stored at 4 °C for up to 1 week before continuing to step 10. 10. After 1 h, centrifuge samples at 1,500g for 45 min at 4 °C. A white pellet should be visible after centrifugation.  crItIcal step The presence of a white pellet does not guarantee the presence of competent viral particles. Verification of active virus must still be performed by the researcher. 11. Gently aspirate the supernatant, being careful not to disturb the pellets. Resuspend the pellets in 500 µl of lentiviral storage buffer per 10-cm dish used to make virus (i.e., if four 10-cm dishes of HEK 293T cells were used to produce the ERG1 virus, then this pellet should be resuspended in 2 ml of lentiviral storage buffer). Dispense the resuspended pellets into Eppendorf tubes in 50-µl aliquots, and immediately store them at −80 °C.  crItIcal step The volume of lentiviral storage buffer used to resuspend the viral pellets will vary depending on the efficiency of the lentiviral preparation, and it should be determined empirically by the researcher. We have found that resuspending the viral pellets in 500 µl of storage buffer for each 10-cm dish used to make a particular virus affords a suitable working concentration of virus that can be added in small quantities for infection into ACs.  crItIcal step Once the lentivirus is resuspended in lentiviral storage buffer, it is highly unstable at temperatures below −20 °C. Similarly, repeated freezing and thawing of lentivirus substantially reduces their infection efficiency. As such, we recommend that a single aliquot be thawed and frozen not more than one or two times before infection. In addition, immediately upon thawing, the virus should be added to the ACs for infection. Lentivirus should never be stored at 4 °C, even for short-term storage.  pause poInt Lentivirus can be stored at −80 °C for at least 1 year. 12. Thaw one aliquot on ice for each lentivirus that was generated, and titer the virus using a Lenti-X p24 rapid titer kit (follow the protocol provided by the kit). Calculate the titer in units of picograms per µl, and record the results.  crItIcal step This procedure can take ~4-5 h, and thus we generally conduct the titer assay the day after our viruses have been collected and stored at −80 °C. However, if time permits, the researcher can conduct the titer assay on the same day as the virus was collected and stored. If this is done, it is recommended that the researcher still freeze and then thaw an aliquot of virus, so as to account for any freeze/thaw effects that can alter the titer of the virus.
troubleshooting guidance
If there is a low titer readout, it could be because of low-quality or mutated plasmids (action: verify plasmid integrity by restriction enzyme digestion and/or sequencing); poor lentiviral preparation (action: remake virus); improper use of or faulty p24 kit (action: contact manufacturer for technical assistance); and sub-par HEK293 cells (action: obtain fresh/low-passage HEK293 cells).
expected results
The results of the titering assay will vary depending on the efficiency of the lentiviral preparation (see above for troubleshooting information). Generally, the titers of our lentiviruses fall in the range of 500-5,000 pg µl −1 . If the researcher desires a more concentrated or more diluted stock of the virus, this can be easily achieved by altering the amount of lentiviral storage buffer used to resuspend the viral pellets (step 11 in this box). We prefer this range for our lentiviral stocks, in that we have found that adding ~25,000 pg of each virus per well (six-well format-see the main PROCEDURE section, Step 7) will efficiently infect the ACs for reprogramming into rAC-VECs.
Doxycycline To prepare aliquots of doxycycline for use, dissolve 10 mg of doxycycline into 5 ml of sterile water. This will generate a 2 mg ml −1 stock (1,000×) solution. Dispense 0.5-ml aliquots into tubes and store them at −20 °C to avoid repeated freeze/thaw cycles (good for at least 6 months). When treating cells with doxycycline, thaw one aliquot and remove a suitable amount that will be needed for the duration of the experiment, and then store it at 4 °C (this can be kept at 4 °C for up to 1 month). Fibronectin-coated plates Coat all plates and/or flasks with fibronectin solution (1 mg ml −1 fibronectin in Dulbecco's PBS (DPBS)) before plating of cells. After adding fibronectin solution to plates or flasks, leave them at room temperature (20-25 °C) in a tissue culture hood for a minimum of 30 min. Aspirate fibronectin solution away, and use coated plates or flasks right away for cell plating, or store them at 4 °C (good for at least 3-4 weeks). Plasmids pCCL ETV2, ERG1 and FLI1 constructs To generate constitutively expressing gene products for lentiviral transduction, clone cDNAs encoding ETV2, ERG1 and FLI1 into the lentiviral backbone pCCL-PGK lentivirus vector (our construct work was performed by GeneCopoeia: http://www. genecopoeia.com/). Further modifications to ETV2 and ERG1 can be performed as previously described 21 . Briefly, insert a triple Flag-tag into the amino terminus of ETV2 and ERG1 for the purpose of identification via western blot analysis. The lack of high-quality antibodies to detect human ETV2 and ERG1 necessitates this modification. No Flag-tag needs to be added to human FLI1, because commercial antibodies are sufficient to detect this protein.
The pCCL-PGK-based plasmids are all capable of generating high levels of transcript for each gene of interest. Furthermore, no silencing of these genes is observed during the reprogramming platform (or thereafter). Last, the presence of the Flag-tag has no effect in altering the outcome of the reprogramming strategy. These plasmids are available for noncommercial use from the corresponding author of this paper, S.R., and further information about the availability and design of these plasmids can be obtained by contacting him directly. (See also plasmid maps in Supplementary Manual.) pLVX-Tight-Puro ETV2 Tet-Off construct The ETV2 Tet-Off construct can be generated as previously described 21 . Briefly, the open reading frame of the Flag-tagged ETV2 is subcloned out from the pCCL-PGK ETV2 plasmid (described above) and into the pLVX-Tight-Puro vector to control the expression of ETV2 via doxycycline addition. In the presence of doxycycline, ETV2 is not expressed. At the desired time for the suppression of ETV2, add 1 µl of doxycycline stock per 1 ml of endothelial growth medium (final concentration will then be 2 µg ml −1 ). Treat the plasmid every 2-3 d with fresh doxycycline for the suppression of ETV2. As with the pCCL-PGK-based plasmids (described above), the pLVX-Tight-Puro ETV2 plasmid also shows good expression of the gene product (albeit less expression than the pCCL-PGK ETV2 construct) in the absence of doxycycline, and without any indication of gene silencing over time. Upon treatment with doxycycline, protein expression drops to undetectable levels within 48 h, and it will remain suppressed in the presence of freshly added doxycycline to the medium every 2-3 d. This plasmid is available for noncommercial use from the corresponding author of this paper, S.R., and further information about availability and design of this plasmid can be obtained by contacting him directly. (Also see plasmid maps in Supplementary Manual.) ! cautIon Lentivirus vectors are relatively unstable, and they should be propagated in appropriate bacteria and grown at 30 degrees instead of 37. If virus production is consistently poor, it is possible that features of the vector, such as the long terminal repeats (LTRs), are mutated and damaged. Sequencing of the entire plasmid(s) to determine that it is intact may be necessary if virus production is consistently poor.  crItIcal When you are using the pLVX-Tight-Puro construct plasmid, it is essential that the pTA plasmid (also supplied in the kit from Clontech) be used as well. The pTA plasmid produces the factor that activates the gene of interest (i.e., in this case ETV2) in the Tight-Puro construct plasmid. Therefore, lentiviral particles for both of these plasmids must be made, and subsequently both of these viruses must be co-infected for the expression of ETV2 using this system. proceDure lentivirus preparation • tIMInG ~1 week 1| Generate and titer the lentivirus. The method for lentiviral production that we use is described in Box 1.
Although alternative methods may be used to generate lentivirus, we cannot guarantee similar results of efficacy in the reprogramming platform described herein.
! cautIon This and all subsequent steps in which cells or viruses are manipulated should be conducted in a tissue culture hood, and waste products should be disposed of properly.
culturing of acs • tIMInG ~1 d to 2 weeks 2| Culture ACs to confluency. We obtain AC samples from our cytogenetics department via two distinct formats: 'fresh unmanipulated' ACs and 'precultured' ACs. The procedures for handling these types of samples are described in options A and B below. Unless otherwise directed, ACs obtained from an outside company should be cultured via option B (i.e., precultured procedure).
(a) culture of fresh unmanipulated ac samples  crItIcal step Fresh unmanipulated AC samples are usually received in our laboratory within several hours of their initial collection from the patient. Although it is ideal to immediately transfer these samples into culture conditions as described below, we have found that these samples can be stored at 4 °C for up to 24 h with little loss of cell viability.
(i) Place ACs in a 15-ml conical tube and centrifuge them at 400g for 10 min at 4 °C.
(ii) Aspirate the supernatant, and resuspend the cell pellet in 1 ml of AC growth medium.
(iii) Transfer cells and medium to one well of a 12-well plate, and place the plate in a 37 °C incubator (Fig. 2a) .  crItIcal step AC growth medium should always be prewarmed to 37° in a water bath before use. (iv) After 3 d, transfer the supernatant from the first well to a second well of the same 12-well plate, and re-feed the first well with 1 ml of AC growth medium (Fig. 2b) . Place the 12-well plate in a 37 °C incubator.  crItIcal step It is common to observe that the majority of the cells transferred into the first well of the plate do not adhere to the surface (Fig. 2b) . As such, they are re-plated into a second well to obtain a greater yield of cells. (v) After 3 d, aspirate the supernatant from the first and second wells, and refeed each well with 1 ml of AC growth medium. Place the 12-well plate in a 37 °C incubator. When the wells are confluent (usually in another 7-10 d; see Fig. 2 for typical morphologies of cells), proceed to Step 3.  crItIcal step As was the case in the previous step, it is common that the majority of cells transferred into the second well of the plate do not adhere to the surface. In fact, after aspiration of the first and second wells of the plate, very few cells will be present. This is normal, and expansion of these few cells will begin within the next few days (Fig. 2c-f) .
The majority of these cells will expand into either epithelial (type E) ACs (Fig. 2c,d ) or fibroblastic (type F) ACs (Fig. 2e,f) .
? trouBlesHootInG (B) culture of precultured ac samples  crItIcal step Precultured AC samples are ACs that have already been subjected to culture conditions. An advantage of using these cells is that the quantity of ACs in these samples is substantially higher than that of the fresh unmanipulated AC samples. A disadvantage of using precultured ACs is that they are not freshly collected; rather, they have been passaged several times, and the conditions under which they have been cultured could vary slightly from sample to sample. Furthermore, culturing of ACs with serum and FGF-based growth factors might favor the expansion of mesenchymal and fibroblastic subpopulations over epithelioid subpopulations of ACs. However, it is important to note that our reprogramming strategy is effective to generate rAC-VECs from both mesenchymal and epithelioid subsets of both precultured ACs and fresh unmanipulated ACs.
(i) If the cells arrive in a flask (i.e., live cells), aspirate the medium from the cells and add fresh medium with a suitable amount of AC growth medium. If the flask is already confluent (Fig. 2g) , proceed to 4| Add 2× the amount of AC growth medium that was used to detach the cells to the well or flask (for example, if 1 ml of Accutase was used to detach cells, add 2 ml of AC growth medium to the well or flask). Pipette the mixture up and down around the surface of the well or flask to retrieve maximum number of cells, and transfer to a 15-ml conical tube.
5|
Centrifuge the tube at 400g for 5 min at 4 °C. Aspirate the supernatant, and resuspend the cell pellet in AC growth medium and re-plate it into the desired format (wells or flasks) and incubate. Continue expanding ACs by repeating Steps 3-5 as each successive well or flask becomes confluent. When a desired number of ACs have been accumulated, proceed to Step 6.  crItIcal step When passaging these cells, we generally do not split them at any more than 1:3. For example, when passing a confluent T25 flask of ACs, we would split them into three new T25 flasks (or to one T75 flask). Similarly, one confluent well of a six-well plate is usually passed to three new wells of a six-well plate (or to one T25 flask). However, these splitting ratios can be further optimized by the individual researcher.  crItIcal step If the user so chooses, specific subpopulations of ACs can be purified at this point from the general AC population. However, as re-purification of ACs is not necessary to achieve nor improve the desired outcome of generating numerous rAC-VECs, these steps have been omitted from the current protocol. For details on re-purifying subpopulations of ACs, please refer to the original Ginsberg et al. 21 Cell paper.  pause poInt Alternatively, ACs can be frozen at −80 °C for future use, as described in Box 2. Fig. 3a) . These are standard qPCR or FACS or immunostaining assays, and thus standard procedures can be followed. These and other assays that can assess the efficiency of reprogramming ACs into rAC-VECs have also been previously described 21 .
12|
On days 14 and 15 of the lentiviral infection, collect a small fraction of the cells for processing and analysis, as described in Step 11.  crItIcal step If the TRE-ETV2 construct was used in Step 7, doxycycline should now be used to turn off ETV2 expression: add 1 µl of doxycycline stock per 1 ml of endothelial growth medium to the cells. Continue to culture the cells for a further week, adding fresh doxycycline every 2-3 d (best to add when changing medium) for sustained suppression of ETV2 in TRE-ETV2-transduced cells.
13| By day 21 of the lentiviral infection, the majority of the cells should be stable rAC-VECs. Collect a small fraction of the cells for processing and analysis, as described in Step 11 (see also ANTICIPATED RESULTS and Fig. 3a) . At the discretion of the researcher, rAC-VECs can be further cultured or be frozen down for long-term storage (Box 2). 
